News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Apr 8, 2021

Summary Toggle aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor

Ms. Wilson to advise company on patient strategies related to clinical program for ATYR1923 in pulmonary sarcoidosis SAN DIEGO , April 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on
Mar 23, 2021

Summary Toggle aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update

Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter. Results from ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications demonstrated favorable safety profile and signals of activity based on
Mar 16, 2021

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results

Management to host conference call and webcast on March 23rd at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , March 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways,
Mar 15, 2021

Summary Toggle aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs, consistent with findings from animal models. SAN DIEGO , March 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
Mar 11, 2021

Summary Toggle aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO , March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming American
Mar 10, 2021

Summary Toggle Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor

Dr. Varner to advise company on mechanistic understanding of Neuropilin-2 (NRP2) and the development of novel anti-NRP2 antibody therapeutics for cancer SAN DIEGO , March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and
Feb 25, 2021

Summary Toggle aTyr Pharma to Present at March Investor Conferences

SAN DIEGO , Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present at four virtual investor conferences in March.
Feb 11, 2021

Summary Toggle aTyr Pharma Announces New tRNA Synthetase Discovery Programs

Advancement of selected AARS and DARS fragments primarily targeting cancer Programs will accelerate discoveries initially focusing on natural killer (NK) cell biology SAN DIEGO , Feb. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery
Feb 9, 2021

Summary Toggle aTyr Pharma to Present at BIO CEO & Investor Digital Conference

SAN DIEGO , Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive Officer,
Jan 25, 2021

Summary Toggle aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression

Poster highlights NRP2 expression on immune cells in the tumor microenvironment. Company's lead NRP2 antibody, ATYR2810, is in development for oncology. SAN DIEGO , Jan. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development